Explore the vast range of titles available.

[...]lower concentrations of 1,5-AG correlate with more frequent hyperglycemic episodes (most commonly postprandial hyperglycemia) and reflect trends over a 1- to 2-week timeline. 1,5-AG is currently marketed for clinical use under the trade name GlycoMark® in the US, despite the limited information regarding its potential role in clinical practice. [...]when combined with traditional clinical risk factors and Hb A1c, concentrations of 1,5-AG did not meaningfully improve the predictive model performance for retinopathy, CKD, or diabetes in the overall ARIC study population.